Corcept Therapeutics Incorporated shares owned by Renaissance Technologies
Quarter-by-quarter ownership of Corcept Therapeutics Incorporated (CORT) shares owned by Renaissance Technologies
from 13F filings
Historical chart of Renaissance Technologies investment in Corcept Therapeutics Incorporated
Tip: Access up to 7 years of quarterly data
All positions including Corcept Therapeutics Incorporated held by Renaissance Technologies consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Corcept Therapeutics Incorporated by Renaissance Technologies
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2023-09-30 | $180M | 6.6M | 27.25 |
| 2023-06-30 | $149M | 6.7M | 22.25 |
| 2023-03-31 | $147M | 6.8M | 21.66 |
| 2022-12-31 | $148M | 7.3M | 20.31 |
| 2022-09-30 | $185M | 7.2M | 25.64 |
| 2022-06-30 | $186M | 7.8M | 23.78 |
| 2022-03-31 | $175M | 7.8M | 22.52 |
| 2021-12-31 | $159M | 8.0M | 19.80 |
| 2021-09-30 | $162M | 8.2M | 19.68 |
| 2021-06-30 | $188M | 8.5M | 22.00 |
| 2021-03-31 | $209M | 8.8M | 23.79 |
| 2020-12-31 | $244M | 9.3M | 26.16 |
| 2020-09-30 | $167M | 9.6M | 17.41 |
| 2020-06-30 | $150M | 8.9M | 16.82 |
| 2020-03-31 | $99M | 8.3M | 11.89 |
| 2019-12-31 | $94M | 7.8M | 12.10 |
| 2019-09-30 | $92M | 6.5M | 14.14 |
| 2019-06-30 | $62M | 5.6M | 11.15 |
| 2019-03-31 | $59M | 5.1M | 11.74 |
| 2018-12-31 | $62M | 4.6M | 13.36 |
| 2018-09-30 | $62M | 4.4M | 14.02 |
| 2018-06-30 | $68M | 4.3M | 15.72 |
| 2018-03-31 | $79M | 4.8M | 16.45 |
| 2017-12-31 | $90M | 5.0M | 18.06 |
| 2017-09-30 | $71M | 3.7M | 19.30 |
| 2017-06-30 | $32M | 2.7M | 11.80 |
| 2017-03-31 | $20M | 1.9M | 10.96 |
| 2016-12-31 | $11M | 1.5M | 7.26 |
| 2016-09-30 | $3.6M | 560k | 6.50 |
| 2016-06-30 | $1.7M | 311k | 5.46 |
| 2016-03-31 | $896k | 191k | 4.68 |
| 2015-12-31 | $2.3M | 460k | 4.98 |
| 2015-09-30 | $1.7M | 452k | 3.76 |
| 2015-03-31 | $310k | 55k | 5.60 |
Top funds holding Corcept Therapeutics Incorporated
View all funds holding Corcept Therapeutics Incorporated